Circulating Biomarker Panels in Alzheimer's Disease

Gerontology

Volumn 61, Issue 6, 2015, Pages 497-503

  Zafari, Sachli ^a   Backes, Christina ^a   Meese, Eckart ^b   Keller, Andreas ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Biomarkers

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA; MICRORNA 125B; MICRORNA 137; MICRORNA 146A; MICRORNA 29A; MICRORNA 29B; MICRORNA 34A; MICRORNA 9; MICRORNA LET 7D 5P; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BIPOLAR DISORDER; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEPRESSION; EARLY DIAGNOSIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION PROFILING; HUMAN; LIPIDOMICS; LUMBAR PUNCTURE; MASS SPECTROMETRY; NEXT GENERATION SEQUENCING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SCHIZOPHRENIA; BLOOD; METABOLISM; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; BIOMARKERS; HUMANS; MICRORNAS; SENSITIVITY AND SPECIFICITY;

EID: 84946473585     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000375236     Document Type: Review

References (59)

1. Alzheimer's Association: 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011; 7: 208-244.
2. Huang HC, Jiang ZF: Accumulated amyloid-β peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J Alzheimers Dis 2009; 16: 15-27.
3. Langbaum JB, et al: Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol 2013; 9: 371-381.
4. Blennow K, et al: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144.
5. Hampel H, et al: Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008; 4: 38-48.
6. Ma X, et al: DNA methylation data analysis and its application to cancer research. Epigenomics 2013; 5: 301-316.
7. O'Bryant SE, et al: A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One 2011; 6:e28092.
8. Snyder HM, et al: Developing novel bloodbased biomarkers for Alzheimer's disease. Alzheimers Dement 2014; 10: 109-114.
9. McNeill E, Van Vactor D: MicroRNAs shape the neuronal landscape. Neuron 2012; 75: 363-379.
10. Augustin R, et al: Computational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10. BMC Med Genet 2012; 13: 35.
11. Leidinger P, et al: A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol 2013; 14:R78.
12. Etheridge A, et al: Extracellular microRNA: a new source of biomarkers. Mutat Res 2011; 717: 85-90.
13. Guzman-Martinez L, Farias GA, Maccioni RB: Emerging noninvasive biomarkers for early detection of Alzheimer's disease. Arch Med Res 2012; 43: 663-666.
14. Henriksen K, et al: The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 2014; 10: 115-131.
15. Rye PD, et al: A novel blood test for the early detection of Alzheimer's disease. J Alzheimers Dis 2011; 23: 121-129.
16. Lunnon K, et al: A blood gene expression marker of early Alzheimer's disease. J Alzheimers Dis 2013; 33: 737-753.
17. Brys M, et al: Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis 2009; 16: 351-362.
18. Wright BL, Lai JT, Sinclair AJ: Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol 2012; 259: 1530-1545.
19. Anoop A, et al: CSF biomarkers for Alzheimer's disease diagnosis. Int J Alzheimers Dis 2010; 2010: 606802.
20. Rosen C, et al: Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener 2013; 8: 20.
21. Formichi P, et al: Cerebrospinal fluid tau, Aβ, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol 2006; 208: 39-46.
22. Brys M, et al: Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2009; 30: 682-690.
23. Blennow K: CSF biomarkers for mild cognitive impairment. J Intern Med 2004; 256: 224-234.
24. Liu CC, et al: Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9: 106-118.
25. Schmidt C, et al: Cerebrospinal fluid apolipoprotein E concentration and progression of Alzheimer's disease. J Alzheimers Dis 2015; 43: 1229-1236.
26. Vanderstichele H, et al: Analytical performance and clinical utility of the INNOTEST ® PHOSPHO-TAU (181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006; 44: 1472-1480.
27. Maccioni RB, et al: Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol Aging 2006; 27: 237-244.
28. de Leon MJ, et al: Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006; 27: 394-401.
29. de Leon MJ, et al: MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med 2004; 256: 205-223.
30. Turnbull DK, Shepherd DB: Post-dural puncture headache: pathogenesis, prevention and treatment. Br J Anaesth 2003; 91: 718-729.
31. Cedazo-Minguez A, Winblad B: Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Exp Gerontol 2010; 45: 5-14.
32. Borroni B, et al: Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets. Exp Gerontol 2010; 45: 53-56.
33. Keller A, et al: A minimally invasive multiple marker approach allows highly efficient detection of meningioma tumors. BMC Bioinformatics 2006; 7: 539.
34. Huang JX, et al: High-throughput genomic and proteomic analysis using microarray technology. Clin Chem 2001; 47: 1912-1916.
35. Ray S, et al: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-1362.
36. O'Bryant SE, et al: A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 2010; 67: 1077-1081.
37. Hye A, et al: Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 2014; 10: 799-807.
38. Buerger K, et al: Blood-based microcirculation markers in Alzheimer's disease - diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio. Biol Psychiatry 2009; 65: 979-984.
39. Doecke JD, et al: Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 2012; 69: 1318-1325.
40. Di Paolo G, Kim TW: Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 2011; 12: 284-296.
41. Wood PL: Lipidomics of Alzheimer's disease: current status. Alzheimers Res Ther 2012; 4: 5.
42. Mapstone M, et al: Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014; 20: 415-418.
43. Hartmann T, et al: A nutritional approach to ameliorate altered phospholipid metabolism in Alzheimer's disease. J Alzheimers Dis 2014; 41: 715-717.
44. Sullivan PF, Fan C, Perou CM: Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006; 141B:261-268.
45. Booij BB, et al: A gene expression pattern in blood for the early detection of Alzheimer's disease. J Alzheimers Dis 2011; 23: 109-119.
46. Grunblatt E, et al: Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J Alzheimers Dis 2009; 16: 627-634.
47. Fehlbaum-Beurdeley P, et al: Validation of AclarusDx TM , a blood-based transcriptomic signature for the diagnosis of Alzheimer's disease. J Alzheimers Dis 2012; 32: 169-181.
48. Geekiyanage H, et al: Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol 2012; 235: 491-496.
49. Zen K, Zhang CY: Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012; 32: 326-348.
50. Tan L, et al: Circulating miR-125b as a biomarker of Alzheimer's disease. J Neurol Sci 2014; 336: 52-56.
51. Tan L, et al: Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. J Alzheimers Dis 2014; 40: 1017-1027.
52. Kiko T, et al: MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J Alzheimers Dis 2014; 39: 253-259.
53. Sheinerman KS, Umansky SR: Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front Cell Neurosci 2013; 7: 150.
54. McClean PL, et al: The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011; 31: 6587-6594.
55. Beeri MS, et al: The effects of cardiovascular risk factors on cognitive compromise. Dialogues Clin Neurosci 2009; 11: 201-212.
56. Kumar P, et al: Circulating miRNA biomarkers for Alzheimer's disease. PLoS One 2013; 8:e69807.
57. Alexandrov PN, et al: MicroRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol 2012; 3: 365-373.
58. Teplyuk NM, et al: MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol 2012; 14: 689-700.
59. Galimberti D, et al: Circulating miRNAs as potential biomarkers in Alzheimer's disease. J Alzheimers Dis 2014; 42: 1261-1267.